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Nanovesicles from adipose-derived 
mesenchymal stem cells inhibit 
T lymphocyte trafficking and 
ameliorate chronic experimental 
autoimmune encephalomyelitis
Alessia Farinazzo1, Stefano Angiari2, Ermanna Turano1, Edoardo Bistaffa1, Silvia Dusi2,  
Serena Ruggieri2, Roberta Bonafede1, Raffaella Mariotti1, Gabriela Constantin2 &  
Bruno Bonetti1,3
Cell based-therapies represent promising strategies for the treatment of neurological diseases. We 
have previously shown that adipose stem cells (ASC) ameliorate chronic experimental autoimmune 
encephalomyelitis (EAE). Recent evidence indicates that most ASC paracrine effects are mediated by 
extracellular vesicles, i.e. micro- and nanovesicles (MVs and NVs). We show that preventive intravenous 
administration of NVs isolated from ASC (ASC-NVs) before disease onset significantly reduces the 
severity of EAE and decreases spinal cord inflammation and demyelination, whereas therapeutic 
treatment with ASC-NVs does not ameliorate established EAE. This treatment marginally inhibits 
antigen-specific T cell activation, while reducing microglial activation and demyelination in the spinal 
cord. Importantly, ASC-NVs inhibited integrin-dependent adhesion of encephalitogenic T cells in 
vitro, with no effect on adhesion molecule expression. In addition, intravital microscopy showed that 
encephalitogenic T cells treated with ASC NVs display a significantly reduced rolling and firm adhesion 
in inflamed spinal cord vessels compared to untreated cells. Our results show that ASC-NVs ameliorate 
EAE pathogenesis mainly by inhibiting T cell extravasation in the inflamed CNS, suggesting that 
NVs may represent a novel therapeutic approach in neuro-inflammatory diseases, enabling the safe 
administration of ASC effector factors.
Multiple sclerosis (MS) and its animal model experimental autoimmune encephalomyelitis (EAE) are 
immune-mediated disorders of the central nervous system (CNS), characterized by inflammation, demyelination 
and axonal degeneration1,2. Pre-clinical data obtained in EAE models show that adult stem cell-based therapies 
contribute to the prevention and/or repair of the CNS damage by a dual mechanism: modulating the immune 
system when administered in the pre-clinical phase and promoting remyelination through the activation of oligo-
dendrocyte precursors when injected in the chronic phase of disease3–11. Among stem cell sources, mesenchymal 
stem cells (MSC) are stromal progenitor cells derived from different tissues that represent a promising therapeutic 
tool for autoimmune inflammatory diseases like MS, due to their immuno-modulatory effect and neuroprotective 
ability7. Adipose-derived MSC (ASC) can be easily isolated from adipose tissue and share morphology, immune 
phenotype, rate of isolation and paracrine behavior with bone marrow-derived MSC12,13. ASC limit EAE induc-
tion and ameliorate chronic EAE when administered after disease stabilization, leading to the reduction of CNS 
inflammation and demyelination and induction of local neuroregeneration11.
Stem cells (SC) injected systemically can stably integrate for prolonged time periods in target and non-target 
organs with unpredictable consequences, and a number of concerns have been raised in relation to the poten-
tial side effects of SC-based therapies. Among these, several studies have shown that tumor growth depends 
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on the interaction with stromal cells and MSC may promote tumor cell growth by modulating tumor 
micro-environment14,15. In addition, SC injected at high concentration into tissues form aggregates and may 
generate their own microenvironment, leading to the formation of bone nodules or other undesirable structures. 
Furthermore, MSC rapidly undergo cell-to-cell adhesion with the risk of pulmonary emboli or infarctions if not 
carefully prepared for intravenous infusion16.
A growing body of literature indicates that ASC exert their action by producing soluble factors, which mod-
ify the microenvironment resulting in neuroprotective and immuno-modulating effects17–19, and this paracrine 
effect provide the basis for an attractive non-cell-based therapy for autoimmune disorders. Among these factors, 
two types of extracellular vesicles have been recently studied: nanovesicles (NVs) and the larger microvesicles 
(0.1–1 µm)20,21. NVs are 40–100 nm diameter vesicles that are secreted upon fusion of multivesicular endosomes 
with the plasma membrane, serving as information packets, which can be transferred to other cells and modu-
late their functions22,23. The protein composition of NVs varies depending on the cell type of origin and unique 
tissue/cell type signatures have been identified for NVs. However, in spite of their cellular origin, a conserved set 
of proteins are common to NVs, including ALG-2-interacting protein X (Alix), Tumor susceptibility gene 101 
(TSG101), CD9, CD81 and heat-shock protein 70 (HSP70)24.
Here we show that the preventive administration of NVs isolated from ASC (ASC-NVs) ameliorates chronic 
EAE by inhibiting T cell adhesion in inflamed CNS venules and trafficking to the CNS in EAE mice, leading to 
reduced spinal cord inflammation, microglial activation and demyelination. Differently from their parental cells, 
ASC-NVs had no effect when administered at disease onset and displayed limited effect on T cell activation and 
cytokine production. Our data suggest that ASC-NVs may represent a novel therapeutic approach for neurolog-
ical autoimmune diseases, including MS.
Results
Preventive administration of ASC-NVs reduces clinical severity and neuropathological changes 
in chronic EAE. Our previous studies have shown that systemic treatment with ASC during the preclinical 
phase of disease prevents chronic EAE development11. To assess the effect of ASC-NVs on EAE, we produced 
NVs from cultured ASC and characterized them by western blot (Fig. 1). Mice immunized with MOG35–55 pep-
tide were treated with PBS (control animals) or NVs before the clinical signs of disease (Fig. 2a) or at disease 
onset (Fig. 2b). Control mice developed the first clinical signs of EAE at 16.3 ± 1.2 days post-immunization (dpi) 
(mean ± SEM), reached a peak around 20 dpi and then presented a stable disease course, typical of this chronic 
EAE model (Fig. 2a and Table 1). Notably, differently from their parental ASC, treatment with ASC-NVs after 
disease onset failed to modify the clinical course of EAE (Fig. 2b). As expected, the pathological analysis of 
spinal cord sections in all control mice showed the presence of demyelinated areas and inflammatory infiltrates 
(Fig. 2c,d). Notably, mice treated with ASC-NVs before disease onset showed a drastic reduction of the mean clin-
ical score (Fig. 2a), maximum clinical score and cumulative score (Table 1), compared to control animals. In addi-
tion, neuropathological studies showed a significant reduction of the areas of demyelination and in the number 
of CD3+ T cells infiltrating the CNS at disease peak (Fig. 2c,d; Table 1). Taken together, these results demonstrate 
that ASC-NVs prevent chronic EAE development by limiting immune cell infiltration and CNS inflammation, 
whereas had no effect once inflammatory cells have already entered the CNS.
ASC-NVs inhibit microglia activation in vitro and in vivo. To investigate the underlying mechanisms 
responsible for the beneficial effect observed after the treatment with ASC-NVs, we firstly assessed the effect of 
Figure 1. Characterization of ASC-NVs by western blot analysis. Protein lysates from ASC cells and ASC-NV 
fractions were separated on polyacrylamide gels and probed with specific NVs markers. In NV fractions, a 
single band at 70 kDa and around to 25 kDa was present after incubation with HSP70 and CD9 antibodies, 
respectively. Similarly, the treatment with anti-TSG101 antibody displayed an intense signal at 48 kDa in NV 
populations. Moreover, ASC cells expressed both HSP70 and TSG101 markers whereas showed weak reactivity 
against CD9 antibody.
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ASC-NVs on microglial cells. We performed in vitro assays to analyze the impact of ASC-NVs on the N9 murine 
microglial cell line. Treatment of N9 cells with ASC-NVs significantly inhibited their basal and LPS-induced pro-
liferation (Fig. 3a). Concerning in vivo experiment, we analyzed the impact of NVs treatment on microglia acti-
vation on EAE mice. In accordance with in vitro results, we found that the number of Iba-1+ cells was significantly 
reduced in the spinal cord of NV-treated animals, compared to CTRL mice (Fig. 3b), confirming that ASC-NVs 
may inhibit the activation of microglial cells both in vitro and in vivo.
ASC-NVs partially reduce CD4+ T lymphocyte activation in vitro but not in vivo. We next ana-
lyzed the immuno-modulatory activity of ASC-NVs on T cells. Proliferation assays performed in vitro showed 
that ASC-NVs partially inhibited antigen-specific T cell proliferation, reaching a maximum of 30% reduction 
(Fig. 4a). This effect was accompanied by global reduction of cytokine production by proliferating T cells, as 
assessed by Multiplex assay. The presence of ASC-NVs in cell cultures reduced both pro- (i.e. IL-1β, IL-1α, IL-6, 
Figure 2. Preventive administration of ASC-NVs ameliorates EAE course. (a) MOG35–55-immunized C57Bl/6 
mice were treated with PBS (CTRL condition) or 5 μg ASC-NVs at 3, 8 and 13 dpi (red arrows). ASC-NVs 
significantly inhibited the mean clinical score and chronic EAE development, compared to CTRL condition 
(day 14 p = 0.041; day 15 p = 0.019; day 16 p = 0.048; day 17 p = 0.045; day 18 p = 0.046; day 19 p = 0.044; 
day 20 p = 0.033; day 21 p = 0.021; day 22 p = 0.019; day 23 p = 0.020; day 24 p = 0.030; day 25 p = 0.018; day 
26 p = 0.018; day 27 p = 0.018; day 28 p = 0.030; day 29 p = 0.049; day 30 p = 0.048; day 31 p = 0.048; day 32 
p = 0.041; day 33 p = 0.032; day 34 p = 0.032; day 35 p = 0.024). Data are the mean ± SEM of three independent 
experiments, for a total of 15 mice/condition. Results are also summarized in Table 1. (b) MOG35–55-immunized 
C57Bl/6 mice were treated with PBS (CTRL condition) or 5 μg ASC-NVs at 12, 16 and 20 dpi (red arrows). ASC-
NVs did not impact EAE development when injected after disease onset. Data are the mean ± SEM of 9 mice/
condition. (c) Woelcke staining of lumbar spinal cords showed a reduction of demyelination in mice treated 
with ASC-NVs, compared to control mice (p = 6.19E-06). Such beneficial effect by ASC-NVs is markedly visible 
in the blow-up. See also Table 1 for quantification. (d) Immunohistochemistry for CD3+ T lymphocytes on 
serial sections showed a decreased number of infiltrating CD3+ T cells in EAE lesions from mice treated with 
ASC-NVs, compared to controls (p = 0.02), as evident in the inserts. See also Table 1 for quantification. For (c) 
and (d), the data are the mean ± SEM of three independent experiments.
Disease 
onset
Mean maximum 
score
Mean cumulative 
score
Demyelinated 
areaa,b CD3+ cells/mm2 a
Control 
(16 mice) 16.3 ± 1.2 3.1 ± 0.4 42.8 ± 6.4 6.5 ± 0.5 168.7 ± 50.4
ASC-NVs 
(15 mice) 18.2 ± 1.4
1.7 ± 0.3*
p = 0.01
21.8 ± 5.3**
p = 0.002
1.6 ± 0.3***
p = 0.0002
34.4 ± 6.2****
p = 0.00004
Table 1. Clinical and pathological features of NV-treated EAE mice. The table report the data concerning 
disease onset, mean maximum/cumulative score, demyelinated area of spinal cord and the quantification of 
CD3+ cells of NV-treated EAE mice compared to control mice. aMice sacrificed at disease peak. b% of total SC 
area.
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IL-17, IFN-γ, GM-CSF and TNF-α) and anti-inflammatory (IL-10, IL-4 and IL-5) cytokine secretion by T cells 
(Fig. 4b), suggesting that ASC-NVs partially limit T cell activation in vitro.
Based on in vitro results, we sought to determine if ASC-NVs limited T cell activation also in vivo in EAE 
mice. To this purpose, we injected EAE mice treated or not with ASC-NVs with CFSE-labeled cells from lymph 
nodes and spleens of naïve 2D2 TCR-transgenic mice, which display a TCR specific for MOG peptide on their T 
lymphocytes. Cells were injected at 8 dpi in EAE recipient mice, which already received two systemic injections 
of NVs. Three days later, we evaluated the proliferation of CD4+ CFSE+ T cells in recipient mice by flow cytom-
etry. We found that exogenous T cells efficiently proliferated in NV-treated mice, and their proliferation rate was 
comparable to those observed in control animals (Fig. 5a,b). These results suggest that ASC-NVs display a limited 
influence on T cell activation in vivo. Importantly, treatment with ASC-NVs also did not affect the percentage of 
Foxp3+CD25+ regulatory T cells (Tregs) in both lymph nodes and spleens of EAE mice (Fig. 5c), confirming lack 
of immune regulation by ASC-NVs in vivo.
ASC-NVs inhibit integrin-dependent chemokine-induced T cell adhesion in vitro. The observa-
tion that ASC-NVs significantly reduce the number of T cells infiltrating EAE lesions prompted us to investigate 
their effect on the adhesion machinery of activated T lymphocytes. We first checked whether the administration 
of ASC-NVs affected the expression of adhesion molecules in EAE lesions. Immunohistochemical analysis per-
formed on spinal cord slices from control and NV-treated animals at disease onset and peak showed no signif-
icant differences in the expression of ICAM-1, VCAM-1, P-selectin and E-selectin, suggesting that NVs do not 
impact endothelial activation during EAE (data not shown).
We next tested the direct effect of ASC-NVs on activated T cell adhesion on purified integrin ligands. 
Activated T cells were obtained by stimulation with MOG35–55 peptide of splenocytes from 2D2-TCR transgenic 
mice. We observed that 24 hours pre-incubation with ASC-NVs did not significantly affect the spontaneous T 
cell adhesion on both ICAM-1 and VCAM-1 (Fig. 6a). However, treatment of T lymphocytes with 15 or 30 ng/
ml ASC-NVs strongly inhibited rapid adhesion triggered by CXCL12 chemokine (Fig. 6a). To note, treatment 
with NVs did not reduce adhesion molecule expression by activated T cells (Fig. 6b), suggesting that ASC-NVs 
selectively interfere with the signaling machinery required for integrin activation and high integrin affinity state 
induced by chemokines in activated T lymphocytes.
ASC-NVs inhibit activated T cell adhesion in spinal cord venules in EAE mice. The results obtained 
in in vitro adhesion assays (Fig. 6), together with the immunohistochemical analysis in mice treated with NVs 
(Fig. 2), suggest that ASC-NVs reduce immune cell trafficking to the CNS of EAE mice. To confirm that NVs 
impact activated T cell adhesion in vivo, we performed intravital microscopy experiments in the inflamed spinal 
cord of EAE mice at disease peak. To this purpose, MOG35–55-specific encephalitogenic T cells were treated in 
vitro with PBS (control cells) or 30 ng/ml ASC-NVs for 24 hours, and then tested for their adhesion capacity in 
intravital microscopy experiments performed on exposed spinal cord. We found that control cells efficiently 
interacted with endothelium in spinal cord pial venules at disease peak, with the majority of interacting cells 
performing rolling on the vascular bed, while a lower percentage of T cells firmly adhered (Fig. 7a,b). Notably, 
pre-treatment of MOG-specific T cells with ASC-NVs strongly reduced their ability to roll and firmly adhere in 
spinal cord vessels (Fig. 7a,b). These data confirm the results from in vitro adhesion assays and neuropathological 
studies, suggesting that ASC-NVs inhibit EAE development in part by blocking immune cell adhesion in acti-
vated spinal cord pial venules during disease development.
Figure 3. ASC-NVs inhibit microglial cell activation in vitro and in vivo. (a) N9 cells were incubated with LPS 
100 ng/ml for 24 h and then treated with 15 ng/ml and 30 ng/ml of ASC-NVs for 48 h. ASC-NVs significantly 
inhibited microglial cell proliferation in vitro (cntrl basal vs cntrl LPS p = 0.035; cntrl basal vs NVs30 p = 0.039; 
cntrl LPS vs NVs15 p = 0.020; cntrl LPS vs NVs30 p = 0.012). Data are presented as fluorescence arbitrary units 
(a.u.) relative to the basal condition and are mean ± SD of a representative experiment performed in triplicate. 
(b) Evaluation of microglial activation in the spinal cord spinal cord of PBS (CTRL) or NV-treated EAE mice 
at disease peak. Activated microglial cells were identified by immunohistochemistry, following staining with 
anti-Iba-1 antibody. Treatment with NVs strongly inhibited microglial activation in EAE mice, as evident 
by the reduced number of Iba-1+ cells in the spinal cord of NV-treated animals (p = 8.11E-06). Data are the 
mean ± SEM of three independent experiments.
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Discussion
Stem cells are a promising approach for the treatment of autoimmune diseases of the CNS due to their 
immuno-modulatory effects and neuroregenerative potential, thus offering the opportunity to treat different 
pathological aspects of pathologies like MS. However, a major concern regarding cell-based therapies is related 
to the fate of systemically injected MSC, which have been demonstrated to stably integrate for prolonged time 
periods in target and non-target organs, with unpredictable consequences.
Growing consensus supports the idea that most of biological effects mediated by stem cells are due to parac-
rine mechanisms17–19,25. In this regard, it has been recently shown that the administration of conditioned medium 
from MSC may mimic the beneficial effects of MSC administration, indicating that MSC engraftment is not 
Figure 4. ASC-NVs partially inhibit MOG35–55-specific CD4+ T cell proliferation and cytokine production in 
vitro. (a) CD4+ cells isolated from lymph nodes and spleens of 2D2-TCR mice were re-stimulated in vitro for 3 
days with increasing concentrations of MOG35–55 peptide, in the presence of irradiated antigen-presenting cells 
and PBS (CTRL condition) or 30, 15 or 6 ng/ml of ASC-NVs. Cell proliferation was assessed by [3H]-thymidine 
incorporation and expressed as counts per minute (CPM). ASC-NVs partially reduced antigen-specific T 
cell proliferation in a dose-dependent manner, when compared with control cells (*p < 0.05). Data are the 
mean ± SEM of three independent experiments performed in triplicate. (b) Secretion of cytokines (pg/ml) in 
supernatants by proliferating CD4+ T cells was also significantly affected by ASC-NVs, compared to the control 
condition (*p < 0.05). Data are the mean ± SD of one representative experiment from a series of two with 
similar results.
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Figure 5. ASC-NVs do not impact CD4+ T cell activation in vivo in EAE mice. 15 × 106-CFSE labeled lymph 
node and spleen cells from 2D2 mice were injected 8 dpi in EAE recipient mice previously treated with two PBS 
(CTRL) or ASC-NV injections at 3 and 8 dpi. (a) Representative plots from one control and one NV-treated 
mouse showing the proliferation of exogenous CD4+CFSE+ T cells detected as CFSE dilution from the original 
T cell population. (b) Samples were analyzed with FlowJo software to quantitatively assess T cell proliferation 
in recipient mice. No differences were observed between the proliferation of exogenous CD4+ T cells in control 
or NV-treated animals. Data are the mean ± SD of five mice/condition. (c) Quantification of Foxp3+CD25+ 
regulatory T cells (Tregs) in draining lymph nodes and spleens of EAE mice. Lymph nodes and spleens were 
collected at disease peak from EAE mice treated with PBS (CTRL) or ASC-NVs at day +3, +8 and +13 post-
immunization (preventive treatment). Treatment with NVs did not impact the amount of Tregs in both lymph 
nodes and spleens. Data are shown as % of Foxp3+CD25+ Tregs on the total CD3+CD4+ T cell population and 
are the mean ± SD of 4 mice/condition.
Figure 6. ASC-NVs inhibit activated T cell integrin-dependent adhesion in vitro. (a) MOG35–55-activated 
splenocytes from 2D2-TCR were treated for 24 hours with PBS (CTRL condition) or increasing doses of 
ASC-NVs. Cells were then left spontaneously adhere on purified ICAM-1 or VCAM-1 for 20 min. In some 
experiments, CXCL12 0.5 μM was added for 5 min to analyze chemokine-induced adhesion. Pre-treatment 
with NVs significantly inhibited the integrin-dependent adhesion of activated T cells induced by chemokine 
CXCL12, compared to control condition (ICAM-1: cntrl CXCL12 vs NVs6 CXCL12 p = 0.00011; cntrl CXCL12 
vs NVs15 CXCL12 p = 0.0049; cntrl CXCL12 vs NVs30 CXCL12 p = 0.0022. VCAM-1: cntrl CXCL12 vs 
NVs15 CXCL12 p = 0.00054; cntrl CXCL12 vs NVs30 CXCL12 p = 0.0061). Data are the mean ± SD of three 
independent experiments performed in triplicate. (b) Adhesion molecules expression on MOG-specific 
activated T cells after treatment with PBS (CTRL cells) of 30 ng/ml ASC-NVs. Red line: CTRL cells. Blue line: 
NV-treated cells.
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necessary to impact the disease. In fact, Camussi and colleagues have demonstrated that the administration of 
MVs derived from MSC ameliorated renal functions and improved the survival in an animal model of acute tubu-
lar injury, especially after multiple administrations26,27. Furthermore, it has been shown that conditioned medium 
from MSC reduced the infarct size and improved systolic and diastolic cardiac performance in a mouse model of 
myocardial ischemic injury and the beneficial effect was mediated by soluble factors contained within the 50- to 
100-nm vesicles fraction20,21.
In the present paper, we provide evidence that ASC-NVs represent a safe and efficient approach to treat 
chronic EAE, avoiding the administration of parental cells. Such strategy could represent an easily transferable 
treatment to humans, enabling safe administration by systemic injection. In support of a potential application of 
NVs in humans with CNS diseases, we have recently shown that NVs (as well as MVs) are able to exert neuropro-
tective and neuroregenerative effects in vitro28,29. We reported that ASC-NVs protected neuronal cultures from 
apoptosis after oxidative stress and stimulated the process of remyelination in slice cultures after experimental 
demyelination with lysophosphatidylcholine.
Here we show that ASC-NVs have a significant beneficial effect in vivo when administered in the pre-clinical 
phase of chronic EAE, with amelioration of clinical score and strong reduction of spinal cord inflammation and 
demyelination, whereas they failed to induce any significant change in the clinical course of EAE when injected 
after the disease onset. In our experiments with NVs we tried to mimic the experimental setting previously 
employed with ASC treatment in the EAE model, performing multiple i.v. injections in the pre-clinical phase and 
at the disease onset with NVs obtained from approximately the same number of ASC used to treat the EAE mice. 
Interestingly, the comparison of the results indicates that different mechanisms are probably responsible for the 
beneficial effects exerted by the two treatments. In fact, the injection of ASC (and in general MSC) before the clin-
ical onset induced a strong dose-dependent inhibition of antigen-specific T cells proliferation and a Th1-to-Th2 
shift in their phenotype7,10,11. The effect displayed by ASC-NVs on T cell activation was marginal with a slight 
reduction of T cell proliferation in vitro; we speculate that the lack of effect on T cell activation in vivo reflects 
the fact that ASC-NVs act simultaneously on different immune cell subsets, which exert opposite effects on T 
cell proliferation. To note, a similar difference on proliferation between MSC and their NVs has been reported 
in monocytes: MSC were highly anti-proliferative, whereas NVs had a lower effect30. The effect on cytokine pro-
duction was also significantly different as compared with ASC, since NVs induced a global down-regulation of 
cytokines (both pro- and anti-inflammatory molecules) without any evidence of specific effect on Th1, Th17 or 
Tregs sub-populations. We speculate that the effect of ASC on T cell proliferation and cytokine production is 
in part mediated by paracrine mechanism but mostly depends on cell-cell contacts between ASC/MSC and T 
cells. In addition to T lymphocytes, we focused our attention on microglial cells as possible target of ASC-NVs. 
Intriguingly, ASC-NVs directly induced a down-regulation of proliferation and production of pro-inflammatory 
cytokines by N9 microglial cell line in vitro, confirming a direct impact of ASC-NVs on microglial cell activation. 
Accordingly, treatment with NVs was associated with a significant reduction of activated microglial cells in CNS 
parenchyma of EAE mice. However, we cannot exclude that the reduced microglial activation observed in EAE 
lesions in vivo might be due to a lower degree of inflammation in animals treated with ASC-NVs, compared to 
control mice.
While the injection of ASC and ASC-NVs before the clinical onset induce similar clinical and neuropatholog-
ical effects with strong reduction of infiltrating T lymphocytes and inflammatory lesions, NVs were less efficient 
in inhibiting autoreactive T cell activation. This discrepancy prompted us to evaluate alternative mechanisms 
responsible for the decreased T cell extravasation in inflamed CNS, focusing on leukocyte-endothelial interac-
tion. Since we did not observe significant differences in endothelial expression of adhesion molecules following 
NV treatment in EAE mice, we focused our attention on the modulation of the adhesive capacity of activated T 
Figure 7. ASC-NVs block activated T cell adhesion in vivo in inflamed spinal cord pial vessels in intravital 
microscopy experiments. MOG35–55-activated splenocytes from 2D2-TCR were treated for 24 hours with PBS 
(CTRL condition) or 30 ng/ml NVs. Cells were then fluorescently labeled and injected i.v. in EAE recipient 
mice at disease peak. (a) Pre-treatment with ASC-NVs strongly reduced activated T cell adhesion in spinal 
cord venules, compared to control cells (rolling p = 0.0089; arrest p = 0.0325). Data are from five independent 
experiments, for a total of 28 venules/condition. (b) Representative images of spinal cord pial venules acquired 
during intravital microscopy experiments. Note the reduced number of adhered NV-treated cells, compared to 
control cells. Cells are the white spots inside venules.
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cells by ASC-NVs. Noteworthy, we found that the treatment with ASC-NVs inhibited the chemokine-induced 
adhesion of activated T cells to integrin ligands such as ICAM-1 and VCAM-1 in vitro, but had no effect on adhe-
sion molecule expression, suggesting that NVs interfere with signal transduction pathways controlling integrin 
activation. In order to bind their ligands, integrins need to be activated through signal transduction pathways 
triggered by engagement of chemoattractant receptors, leading to an increased affinity and/or valency31. Our 
results suggest that NVs may inhibit integrin affinity triggering in encephalitogenic T cells. We also evaluated the 
effect of NVs on the adhesion of T cells in inflamed spinal cord pial venules in intravital microscopy studies32. 
We observed that encephalitogenic T cells treated with ASC-NVs displayed a significant reduction of firm adhe-
sion in inflamed CNS vessels, compared to control cells. These data are in agreement with the reduced leukocyte 
infiltration observed in immunohistochemical analysis and demonstrate an inhibitory effect of NVs on T cell 
adhesion in vivo. To our knowledge, this is a previously unknown mechanism of action of MSC-derived NVs, 
which may help to explain the significant reduction of infiltrating T cells in EAE lesions in the absence of a strong 
anti-proliferative effect.
We finally compared the therapeutic efficacy of ASC-NVs injected at the disease onset. Differently from their 
parental cells, we observed no modification of the clinical course in this experimental setting. This result is not 
surprising on the basis of the previously mentioned anti-adhesive, but not cytostatic effect of ASC-NVs on auto-
reactive T cells, as, in the therapeutic protocol, ASC-NVs have been administered after disease onset (i.e. once 
inflammatory cells already entered the CNS).
In conclusion, our results show that ASC-NVs administered during early disease phases induce a beneficial 
effect in chronic EAE through the inhibition of trafficking of activated T lymphocytes in the inflamed CNS. 
Therefore, we suggest that ASC-NVs may represent a valuable tool for stem cell-based therapy in chronic inflam-
matory diseases of the CNS. However, it is crucial to understand the mechanisms of action of NVs and their 
homing after their administration. To this purpose, the use of labeled NVs with nanoparticles that allow their 
detection by a non-invasive technique, as magnetic resonance imaging, could be useful33. Once defined the mech-
anism(s) of action of ASC-NVs, new therapeutic approaches based on the synergistic effects of NVs with other 
anti-inflammatory molecules (e.g. GM-CSF as Tregs activator34,35) tolerance-mediated treatments through AC 
injection36,37 or drugs with complementary effects (e.g. cytostatic drugs) may be developed.
Methods
Cell Cultures. Murine ASC were obtained from 6–8 weeks old C57Bl/6J mice (Charles River Laboratories). 
The isolation of stromal-vascular fraction from adipose tissue was carried out as previously described27,38. Briefly, 
extracellular matrix was digested with Collagenase A (Roche) and centrifuged at 1200 g. The pellet obtained was 
re-suspended and the stromal fraction was collected by sequential centrifugation and filtration steps. Cells were 
then cultured in complete medium (DMEM + glucose + GlutaMAX ITM + 15% heat-inactivated adult bovine 
serum + penicillin/streptomycin; all from Invitrogen) supplemented with 50 ng/ml HB-EGF (R&D Systems). The 
immune phenotype of murine ASC was characterized by using monoclonal antibodies (mAb) specific for CD106, 
CD9, CD44, CD80, CD138, and Stem cells antigen 1 (Sca1). In addition, the absence of hematopoietic (CD45, 
CD11c, and CD34) and endothelial markers (CD31) was assessed as previously described6. All mAbs were pur-
chased from BD Pharmingen (San Diego). Isotype-matched antibodies were used as controls. For immunophe-
notypic analysis, ASC were incubated at 4 °C for 10 min with 15% adult bovine serum followed by incubation 
with the specific mAb at 4 °C for 30 min. At least 10,000 events were analyzed by flow cytometry on a FACScalibur 
(Becton Dickinson) using the Cell Quest software (Becton Dickinson).
Isolation and characterization of ASC nanovesicles. NVs were isolated from the culture medium of 
murine ASC at 14–18 passages, as previously described27. ASC were grown to confluence and were maintained for 
72 hours in DMEM supplemented with 0.5% of ultracentrifuged FBS to reduce the contamination of FBS-derived 
vesicles. Culture medium (120 ml) from ASC was collected and subjected to two-step centrifugation at 4 °C (80 g 
for 5 min + 1300 g for 10 min) to remove floating cells and debris. NVs were obtained by filtration using a 0.22 µm 
filter (Millipore) and a membrane concentrator (MWCO 5 K, Corning Spin-X UF20) at 3200 g for 90 min at 4 °C. 
The fraction was purified with two ultracentrifugations at 100,000 g (Optima Max-E Ultracentrifuge, Beckman 
Coulter) for 1 hour at 4 °C. The pellet obtained was re-suspended in buffer containing a protease inhibitors cock-
tail (Roche). The protein content was quantified with the BCA protein assay kit, following manufacturer’s instruc-
tions (Pierce). To confirm NV isolation and purity, 15–20 µg of NVs were eluted with loading buffer, boiled for 
5 min and separated in 10% and 12% polyacrylamide gels at 100–150 V. Proteins were transferred onto poly-
vinylidene difluoride membranes (Immobilon P, Millipore) for 2 hours at 60 V in transfer buffer. Membranes 
were then blocked with 10% non-fat dry milk for 1 hour and incubated with anti-CD9 mAb (Millipore; 1:500), 
anti-TSG101 mAb (Abcam; 1:1000) and polyclonal anti-HSP70 (Santa Cruz Biotechnology; 1:1000). After incu-
bation with the appropriate secondary IgG HRP-conjugated antibodies, the membranes were developed with 
ImmobilonTM Western substrate (Millipore) and proteins were visualized on autoradiography film (Hyperfilm, 
Amersham Biosciences).
In vitro and in vivo CD4+ T cell proliferation assays. Myelin oligodendrocyte glycoprotein (MOG)-specific 
CD4+ T cells were isolated from lymph nodes and spleens of 2D2-T cell receptor (TCR)-transgenic mice (the Jackson 
Laboratories39) by magnetic cell sorting, following manufacturer’s instructions (Miltenyi Biotech). An amount of 
0.3 × 106 CD4+ cells were incubated in complete medium (RPMI + 10% FBS + sodium pyruvate 1 mM + penicillin/
streptomycin) in 96-well plates with increasing concentration of MOG35–55 peptide (GenScript), in the presence of 
1.2 × 106 irradiated splenocytes as antigen presenting cells. In some experiments, cells were stimulated in the pres-
ence of 6, 15 or 30 ng/ml ASC-NVs. After 2 days of activation, [3H]-thymidine (1 µCi/well) was added for 18 hours 
www.nature.com/scientificreports/
9SCIENTIFIC REpoRTS |  (2018) 8:7473  | DOI:10.1038/s41598-018-25676-2
before the culture termination. [3H]-thymidine uptake was determined with a µ-counter (Perkin Elmer) after the 
addition of Ultima GoldTM scintillation cocktail (Perkin-Elmer) to each sample.
To assess the effect of ASC-NVs on T cell proliferation in vivo, C57Bl/6 mice were immunized for EAE induc-
tion as described below. PBS (control mice) or 4 μg of ASC-NVs were injected in immunized mice 3 and 8 days 
dpi. 4 hours after the second injection, 15 × 106 total cells from lymph node and spleen of naïve 2D2-TCR mice 
were labeled with green carboxyfluorescein succinimidile ester (CFSE; eBioscience) and infused in immunized 
mice. Three days later (11 dpi), recipient mice were perfused with PBS and draining lymph nodes were collected 
and mechanically dissociated. Cells were labeled with allophycocyanin (APC)-conjugated rat anti-mouse CD4 
antibody (Biolegend) and the proliferation of CD4+CFSE+ T cells was determined by flow cytometry analysis 
with FlowJo software (Tree Star Inc.), as previously described40.
In vitro proliferation assay for microglial N9 cell line. The proliferation of microglial N9 cells was 
assessed by commercial BrdU proliferation Kit (Cell proliferation Elisa, BrdU; Roche Diagnostic Gmbg) accord-
ing to the manufacturer’s instructions. Briefly, N9 cells were seeded into a 24-well plate and stimulated with 
100 ng/ml of lypopolysaccharide (LPS) for 24 h and then treated with 15 ng/ml and 30 ng/ml of NV for further 
48 h. Cells were then incubated with BrdU solution at 37 °C. Absorbance was measured at 450 nm with a spectro-
photometer (BioRad Laboratories). The rate of mitotic activity was proportional to fluorescence emission. Data 
are presented as fluorescence arbitrary units (a.u.) relative to the basal (not stimulated) condition.
MultiPlex assay for cytokines production. Supernatants from proliferation assays in which cells were 
treated with 30 ng/ml NVs were used to evaluate cytokine production by proliferating T cells. A Multiplex 
cytokine assay (MilliPlex, Millipore) was performed, following manufacturer’s instructions. The following 
cytokines were detected and quantified in the assay: interleukin (IL)-1β, IL-1α, IL-4, IL-5, IL-6, IL-10, IL-17, 
interferon (IFN)-γ, granulocyte macrophage colony-stimulating factor (GM-CSF) and tumor necrosis factor 
(TNF)-α.
Preparation of MOG-specific activated T cells. Total splenocytes from 2D2-TCR transgenic mice were 
stimulated in vitro with 30 µg/ml MOG35–55 peptide in complete medium (10 × 106 cells/ml). After 4 days of stim-
ulation, cells were washed, and live cells were isolated by Ficoll-Paque gradient. Cells were then incubated for 
24 hours with PBS (control) or 6, 15 or 30 ng/ml ASC-NVs in complete medium. After 24 hours, cells were washed 
and immediately used for in vitro adhesion assays or intravital microscopy experiments.
In vitro adhesion assays on purified integrin ligands. Glass slides were coated overnight at 4 °C with 
1 µg/ml purified mouse intercellular adhesion molecule (ICAM)-1 or vascular cell adhesion molecule (VCAM)-1 
(R&D Systems) in PBS. MOG-specific T cells were treated with NVs as described above and left to spontaneously 
adhere on ICAM-1 or VCAM-1 for 20 min at 37 °C. In some experiments, chemokine CXCL12 (SDF-1; 0.5 µM) 
was added for 5 min to evaluate the chemokine-induced adhesion. Cells were then immediately fixed in glutaral-
dehyde 1.5% in ice cold PBS and counted by computer-assisted enumeration41.
Flow cytometry. MOG-specific T cells were incubated for 24 hours with 30 ng/ml ASC-NVs. The fol-
lowing rat-anti mouse purified antibodies were used to detect adhesion molecule by antigen-specific spleno-
cytes: anti-lymphocyte function-associated antigen-1 (LFA-1; TIB-213 clone), anti-α4-integrin (PS/2 clone), 
anti-P-selectin glycoprotein ligand-1 (PSGL-1; 4RA10 clone) and anti-CD44 (MJ64 clone). Adhesion molecule 
expression was then quantified by flow cytometry after staining with phycoerythrin (PE)-conjugated secondary 
goat anti-rat antibody (Biolegend).
EAE induction and treatment protocol. Chronic EAE was induced in 6–8 weeks old C57Bl/6 mice by 
subcutaneous immunization with 300 μg of MOG33–35 peptide in complete Freud’s adjuvant (Becton Dickinson) 
containing 0.8 mg/ml Mycobacterium Tuberculosis (Becton Dickinson), as previously described42,43. Mice were 
also injected intravenously (i.v.) with pertussis toxin (40 ng; List Biological Laboratories) at the day of immuniza-
tion and after 48 hours. To evaluate the clinical and pathological efficacy of ASC-NVs in chronic EAE, mice were 
injected i.v. with NVs at 3, 8 and 13 dpi (preventive protocol) or at 12, 16 and 20 dpi (therapeutic protocol). For 
each injection, we infused 5 μg of NVs in 0.3 ml of PBS. Control mice received only vehicle. Clinical score was 
blindly registered according to the following scale: 0 = healthy, 1 = limp tail, 2 = ataxia and/or paresis of hind-
limbs, 3 = paraplegia, 4 = paraplegia with forelimb weakness or paralysis, 5 = moribund or death animal. Animals 
were housed in pathogen-free, climate-controlled facilities and were provided with food and water according to 
current European Community laws. All mouse experiments were carried out in accordance with experimental 
guidelines approved by the University of Verona committee on animal research (Centro Interdipartimentale di 
Servizio alla Ricerca Sperimentale) and by the Italian Ministry of Health.
Histology and immunohistochemistry. Frozen sections were obtained from lumbar and dorsal spinal 
cord and processed for histology and immunohistochemistry at 25 dpi, as previously described (11). Histological 
assessment of spinal cord demyelination (Woelcke staining) and inflammatory infiltrates (hematoxylin and eosin; 
H&E) in lumbo-sacral segments was blindly performed calculating affected areas in at least three sets (100 µm 
apart) of six sections each for every single animal. For immunohistochemistry, anti-CD3 (for T cells; Serotec, 
Oxford, UK) and anti-Iba1 (for monocytes/macrophages; Wako) primary antibodies were incubated overnight. 
The numerical density of microglia and the area of microglial cells were determined in 10 μm spinal cord sections. 
Images were acquired from spinal cord using a LEICA microscope at a magnification of 40× and blindly counted 
with ImageJ v1.32j software.
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To evaluate the expression of cell adhesion molecules, a heat-induced epitope retrieval was required with 
epitope retrieval buffer, pH 8.0 (Leica) at 90 °C. Sections were then treated with 20% normal goat serum (Vector 
Laboratories, Burlingame, CA) and 1% BSA and then incubated with primary antibodies over night at 4 °C. We 
used mAbs to VCAM-1 (1:500, GTX82989 clone, Genetex), P-Selectin (1:10 ab6632 clone, Abcam), ICAM-1 
(1:100, ab2213 clone, Abcam) and E-Selectin (1:20, BBA16 clone, R&D). After washing, appropriated biotiny-
lated secondary antibodies were added; the reaction was visualized with ABC kit (Vector) and Novared Substrate 
Kit (Vector) according to manufacturer instructions. Images of immune-peroxidase were obtained with Zeiss 
Axiophot microscope equipped with Axiocam HCR camera and Axiovision software. Lesions were identified on 
digital images and determined following a manual outline of the lesion border and expressed as percentage of the 
total spinal cord section area. All counts were performed in three sets for each animal.
Intravital microscopy experiments in spinal cord venules. MOG35–55-immunized EAE mice at dis-
ease peak were anesthetized by intraperitoneal injection of ketamine (100 mg/kg body weight)/xylazine (15 mg/
kg) solution. After skin removal, a spinal column stabilization device was made, by mounting STS-A Compact 
Spinal Cord Clamps and MA-6N head holding adaptor on a steel base that was adapted to fit on the microscope’s 
stage. These instruments (Narishige, Japan) were adapted on a customized microscope stage (Siskiyou, USA) in 
our intravital microscopy facility. A midline dorsal incision exposed the lumbar column over L1-L4, the main site 
of inflammation in EAE. Muscles were dissected from the sides of the vertebral bone and laminectomy was per-
formed with micro drill and bone scraper to expose the spinal cord. We left an intact dura mater (approximately 
50 µm) to protect the spinal cord, and further dampened the spinal cord motions by sealing with a drop of low 
melt agarose on the dura and a coverglass. Dorsal spinal cord vessels were visualized by i.v. injection of fluores-
cent dextran (Molecular Probes). MOG35–55-specific T cells were incubated for 24 hours with PBS or 30 ng/ml 
ASC-NVs, and then labeled with 5-(6)-(((4-Chloromethyl)Benzoyl)Amino)Tetramethylrhodamine (CMTMR) 
for 20 min at 37 °C or with 40 mM 5-Chloromethylfluorescein Diacetate (CMFDA) (Molecular Probes, USA) for 
4 min at 37 °C. 30 × 106 cells were injected i.v. in recipient mice immediately before the acquisition. We meas-
ured the number of rolling interactions, rolling velocity, hemodynamic parameters and cell sticking, defined 
as firm adhesion for at least 10 sec. Analysis of intravital microscopy experiments was performed as previously 
described42,44.
Statistical analysis. Data are presented as mean ± standard deviation (SD) or standard error of the mean 
(SEM). Statistical analysis using a two-tailed Student’s t-test was performed to evaluate differences between 
ASC-NVs and control treatments for several parameters. A p value < 0.05 was considered statistically significant 
(*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.00001).
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